Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared With Its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older With 30% or Greater Scalp Hair Loss
In the register
The register attaches this trial to Farudodstat (ASLAN003) (ASLAN Pharmaceuticals), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 2
- Sponsor
- ASLAN Pharmaceuticals
- Participants (registry)
- 60
- Start
- April 2023
- Primary completion
- September 2024
- Study completion
- October 2024
- Last registry update
- December 2023
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: Farudodstat, ASLAN003, Placebo, Placebo Comparator
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.